Financial Analysis: CNBX Pharmaceuticals (CNBX) & Its Peers

Posted by on Jun 23rd, 2023

CNBX Pharmaceuticals (OTCMKTS:CNBX – Get Rating) is one of 405 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare CNBX Pharmaceuticals to similar businesses based on the strength of its earnings, risk, institutional ownership, analyst recommendations, profitability, dividends and valuation.

Valuation and Earnings

This table compares CNBX Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
CNBX Pharmaceuticals N/A N/A -2.80
CNBX Pharmaceuticals Competitors $375.79 million $54.07 million 19.12

CNBX Pharmaceuticals’ competitors have higher revenue and earnings than CNBX Pharmaceuticals. CNBX Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

98.2% of CNBX Pharmaceuticals shares are held by institutional investors. Comparatively, 28.0% of shares of all “Biotechnology” companies are held by institutional investors. 73.5% of CNBX Pharmaceuticals shares are held by company insiders. Comparatively, 23.9% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for CNBX Pharmaceuticals and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CNBX Pharmaceuticals 0 0 0 0 N/A
CNBX Pharmaceuticals Competitors 829 1966 6184 80 2.61

As a group, “Biotechnology” companies have a potential upside of 124.95%. Given CNBX Pharmaceuticals’ competitors higher probable upside, analysts clearly believe CNBX Pharmaceuticals has less favorable growth aspects than its competitors.

Profitability

This table compares CNBX Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CNBX Pharmaceuticals N/A N/A N/A
CNBX Pharmaceuticals Competitors -483.89% -67.84% -25.01%

Summary

CNBX Pharmaceuticals beats its competitors on 5 of the 8 factors compared.

CNBX Pharmaceuticals Company Profile

(Get Rating)

CNBX Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the discovery, development and commercialization of novel cannabinoid-based products and innovative technologies for the treatment of cancer. The company was founded by Eyal Barad on September 15, 2004 and is headquartered in Bethesda, MD.

Receive News & Ratings for CNBX Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNBX Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.